Patients in England and Wales with hereditary angioedema (HAE) should soon have a new treatment option after NICE recommended Takeda’s Takhzyro (lanadelumab) should be funded by the NHS in
AstraZeneca has amended a collaboration agreement with Ironwood Pharmaceuticals, gaining sole responsibility for developing, manufacturing and marketing an irritable bowel syndrome drug in
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
